Viveve Medical (VIVE) 10-Q 7 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 06, 2019
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		1,477,529
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	[1]
Current assets:
Cash and cash equivalents	$ 9,086,000	$ 29,523,000
Accounts receivable, net of allowance for doubtful accounts of $543 and $284 as of September 30, 2019 and December 31, 2018, respectively	2,806,000	5,704,000
Inventory	4,141,000	4,119,000
Prepaid expenses and other current assets	3,051,000	2,558,000
Total current assets	19,084,000	41,904,000
Property and equipment, net	3,066,000	2,916,000
Investment in limited liability company	1,412,000	1,843,000
Other assets	587,000	171,000
Total assets	24,149,000	46,834,000
Current liabilities:
Accounts payable	1,791,000	3,994,000
Total accrued liabilities	4,457,000	6,766,000
Total current liabilities	6,248,000	10,760,000
Note payable, noncurrent portion	31,694,000	30,528,000
Other noncurrent liabilities	997,000	634,000
Total liabilities	38,939,000	41,922,000
Commitments and contingences (Note 8)
Stockholders’ equity (deficit):
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 1,469,789 and 463,630 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively
Additional paid-in capital	168,304,000	160,297,000
Accumulated deficit	(183,094,000)	(155,385,000)
Total stockholders’ equity (deficit)	(14,790,000)	4,912,000
Total liabilities and stockholders’ equity (deficit)	$ 24,149,000	$ 46,834,000
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	[1]
Accounts receivable, allowance for doubtful accounts	$ 543	$ 284
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	1,469,789	463,630
Common stock, shares outstanding (in shares)	1,469,789	463,630
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 1,052,000	$ 4,821,000	$ 5,116,000	$ 14,045,000
Cost of revenue	1,099,000	3,327,000	3,981,000	8,390,000
Gross profit (loss)	(47,000)	1,494,000	1,135,000	5,655,000
Operating expenses:
Research and development	1,449,000	3,442,000	6,831,000	10,870,000
Selling, general and administrative	5,032,000	9,114,000	17,188,000	27,482,000
Restructuring costs			742,000
Total operating expenses	6,481,000	12,556,000	24,761,000	38,352,000
Loss from operations	(6,528,000)	(11,062,000)	(23,626,000)	(32,697,000)
Interest expense, net	(1,209,000)	(1,106,000)	(3,519,000)	(3,239,000)
Other expense, net	(51,000)	(4,000)	(133,000)	(14,000)
Net loss from consolidated companies	(7,788,000)	(12,172,000)	(27,278,000)	(35,950,000)
Loss from minority interest in limited liability company	(168,000)	(132,000)	(431,000)	(539,000)
Comprehensive and net loss	$ (7,956,000)	$ (12,304,000)	$ (27,709,000)	$ (36,489,000)
Net loss per share:
Basic and diluted (in dollars per share)	$ (13.51)	$ (39.07)	$ (54.73)	$ (123.41)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	588,976	314,899	506,329	295,677

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	February 2018 Offering [Member]Common Stock [Member]	February 2018 Offering [Member]Additional Paid-in Capital [Member]	February 2018 Offering [Member]	November 2017 ATM Facility [Member]Common Stock [Member]	November 2017 ATM Facility [Member]Additional Paid-in Capital [Member]	November 2017 ATM Facility [Member]Retained Earnings [Member]	November 2017 ATM Facility [Member]	August 2019 ATM Facility [Member]Common Stock [Member]	August 2019 ATM Facility [Member]Additional Paid-in Capital [Member]	August 2019 ATM Facility [Member]Retained Earnings [Member]	August 2019 ATM Facility [Member]	Consultant [Member]Common Stock [Member]	Consultant [Member]Additional Paid-in Capital [Member]	Consultant [Member]Retained Earnings [Member]	Consultant [Member]	Director [Member]Common Stock [Member]	Director [Member]Additional Paid-in Capital [Member]	Director [Member]Retained Earnings [Member]	Director [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances (in shares) at Dec. 31, 2017																				195,033
Balances at Dec. 31, 2017																					$ 102,981	$ (105,581)	$ (2,600)
Stock-based compensation expense																					645		645
Issuance of common shares from employee stock purchase plan (in shares)																				207
Issuance of common shares from employee stock purchase plan																					65		65
Issuance of restricted shares (in shares)																				221
Issuance of restricted shares																					108		108
Net loss																						(12,669)	(12,669)
Stock offering, net of issuance costs (in shares)	115,000			2,082
Stock offering, net of issuance costs		$ 32,225	$ 32,225		$ 1,011		$ 1,011
Cumulative effect adjustment from adoption of new accounting standard – ASC 606																						177	177
Balances (in shares) at Mar. 31, 2018																				312,543
Balances at Mar. 31, 2018																					137,035	(118,073)	18,962
Balances (in shares) at Dec. 31, 2017																				195,033
Balances at Dec. 31, 2017																					102,981	(105,581)	(2,600)
Net loss																							(36,489)
Stock offering, net of issuance costs (in shares)							2,771
Balances (in shares) at Sep. 30, 2018																				315,226
Balances at Sep. 30, 2018																					139,126	(141,893)	(2,767)
Balances (in shares) at Mar. 31, 2018																				312,543
Balances at Mar. 31, 2018																					137,035	(118,073)	18,962
Stock-based compensation expense																					709		709
Issuance of common shares from employee stock purchase plan (in shares)																				256
Issuance of common shares from employee stock purchase plan																					59		59
Issuance of restricted shares (in shares)																				208
Issuance of restricted shares																					67		67
Issuance of common shares in connection with restricted stock award to employee (in shares)																				1,000
Issuance of common shares in connection with restricted stock award to employee																					256		256
Net loss																						(11,516)	(11,516)
Stock offering, net of issuance costs (in shares)				652
Stock offering, net of issuance costs					171		$ 171
February 2018 Offering issuance costs																					(11)		(11)
Balances (in shares) at Jun. 30, 2018																				314,659
Balances at Jun. 30, 2018																					138,286	(129,589)	8,697
Stock-based compensation expense																					698		698
Issuance of common shares from employee stock purchase plan (in shares)																				286
Issuance of common shares from employee stock purchase plan																					64		64
Issuance of restricted shares (in shares)																				182
Issuance of restricted shares																					47		47
Issuance of common shares in connection with restricted stock award to employee (in shares)																				62
Issuance of common shares in connection with restricted stock award to employee																					20		20
Net loss																						(12,304)	(12,304)
Stock offering, net of issuance costs (in shares)				37			37
Stock offering, net of issuance costs					$ 11		$ 11
Balances (in shares) at Sep. 30, 2018																				315,226
Balances at Sep. 30, 2018																					139,126	(141,893)	(2,767)
Balances (in shares) at Dec. 31, 2018																				463,630
Balances at Dec. 31, 2018																					160,297	(155,385)	4,912	[1]
Stock-based compensation expense																					470		470
Issuance of common shares from employee stock purchase plan (in shares)																				429
Issuance of common shares from employee stock purchase plan																					35		35
Issuance of restricted shares (in shares)												274
Issuance of restricted shares													$ 25		$ 25
Issuance of common shares in connection with restricted stock award to employee (in shares)																				6
Issuance of common shares in connection with restricted stock award to employee																					1		1
Net loss																						(10,029)	(10,029)
Balances (in shares) at Mar. 31, 2019																				464,339
Balances at Mar. 31, 2019																					160,828	(165,414)	(4,586)
Balances (in shares) at Dec. 31, 2018																				463,630
Balances at Dec. 31, 2018																					160,297	(155,385)	4,912	[1]
Net loss																							(27,709)
Stock offering, net of issuance costs (in shares)							0
Balances (in shares) at Sep. 30, 2019																				1,469,789
Balances at Sep. 30, 2019																					168,304	(183,094)	(14,790)
Balances (in shares) at Mar. 31, 2019																				464,339
Balances at Mar. 31, 2019																					160,828	(165,414)	(4,586)
Stock-based compensation expense																					562		562
Issuance of common shares from employee stock purchase plan (in shares)																				602
Issuance of common shares from employee stock purchase plan																					20		20
Issuance of restricted shares (in shares)												250				527
Issuance of restricted shares													$ 11		$ 11		$ 48		$ 48
Issuance of common shares in connection with restricted stock award to employee (in shares)																				6
Issuance of common shares in connection with restricted stock award to employee
Net loss																						(9,724)	(9,724)
Balances (in shares) at Jun. 30, 2019																				465,724
Balances at Jun. 30, 2019																					161,469	(175,138)	(13,669)
Stock-based compensation expense																					503		503
Issuance of common shares from employee stock purchase plan (in shares)																				200
Issuance of common shares from employee stock purchase plan																					1		1
Issuance of restricted shares (in shares)																				378
Issuance of restricted shares																					14		14
Issuance of common shares in connection with restricted stock award to employee (in shares)																				4
Issuance of common shares in connection with restricted stock award to employee
Net loss																						(7,956)	(7,956)
Stock offering, net of issuance costs (in shares)							0	1,004,171			1,004,171
Stock offering, net of issuance costs									$ 6,322		$ 6,322
Reverse stock split - cancellation and payout of fractional shares (in shares)																				(688)
Reverse stock split - cancellation and payout of fractional shares																					(5)		(5)
Balances (in shares) at Sep. 30, 2019																				1,469,789
Balances at Sep. 30, 2019																					$ 168,304	$ (183,094)	$ (14,790)
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019		Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (27,709,000)		$ (36,489,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	260,000		103,000
Depreciation and amortization	819,000		545,000
Stock-based compensation	1,634,000		2,294,000
Fair value of common shares issued			256,000
Non-cash interest expense	1,266,000		1,176,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities	4,000
Loss from minority interest in limited liability company	431,000		539,000
Loss on disposal of property and equipment	93,000
Changes in assets and liabilities:
Accounts receivable	2,638,000		1,119,000
Inventory	(236,000)		(2,317,000)
Prepaid expenses and other current assets	(493,000)		61,000
Other noncurrent assets	40,000		1,000
Accounts payable	(2,203,000)		(1,297,000)
Accrued and other liabilities	(2,566,000)		502,000
Other noncurrent liabilities	160,000		262,000
Net cash used in operating activities	(25,862,000)		(33,245,000)
Cash flows from investing activities:
Purchase of property and equipment	(848,000)		(983,000)
Net cash used in investing activities	(848,000)		(983,000)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	6,322,000		33,407,000
Proceeds from issuance of common shares from employee stock purchase plan	56,000		188,000
Transaction costs in connection with note payable	(100,000)
Reverse stock split - cancellation and payout of fractional shares	(5,000)
Net cash provided by financing activities	6,273,000		33,595,000
Net decrease in cash and cash equivalents	(20,437,000)		(633,000)
Cash and cash equivalents - beginning of period	29,523,000	[1]	20,730,000
Cash and cash equivalents - end of period	9,086,000		20,097,000
Supplemental disclosure:
Cash paid for interest	2,067,000		1,991,000
Cash paid for income taxes			2,000
Supplemental disclosure of cash flow information as of end of period:
Issuance of note payable in settlement of accrued interest	973,000		934,000
Net transfer of equipment between inventory and property and equipment	214,000		210,000
Operating cash outflows from operating leases	220,000
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)	$ 629,000
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency ATM Equity Offerings The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, August 16, 2019, may $6,760,000 “August 2019 $6,760,000 August 2019 September 2019. three September 30, 2019, 1,004,171 August 2019 $6,322,000. September 30, 2019, no August 2019 The Company had previously established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, $25,000,000 “November 2017 August 16, 2019, November 2017 November 7, 2017. no November 2017 three nine September 30, 2019, zero November 2017 three nine September 30, 2018, 37 2,771 November 2017 $11,000 $1,194,000, November 2017 August 2019, 3,364 $1,318,000. Public Offerings In December 2018, “December 2018 147,285 $22,093,000. $20,385,000. In February 2018, “February 2018 115,000 $34,500,000. $32,214,000. Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2018, March 15, 2019. three nine September 30, 2019 not December 31, 2019 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of September 30, 2019, $183,094,000, $9,086,000 $12,836,000. $6,608,000 three September 30, 2019 $25,862,000 nine September 30, 2019. November 2020. not one To fund further operations, the Company will need to raise additional capital. The Company may no not no no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split On September 18, 2019, 1 100 September 18, 2019. not No The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75 The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard - Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2019, two 31 three September 30, 2018, three 42% nine September 30, 2019, one 17 nine September 30, 2018, one 21% There were no 10% three nine September 30, 2019 2018. As of September 30, 2019, four 67% December 31, 2018, three 54% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $543,000 September 30, 2019 $284,000 December 31, 2018. Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System have a rental period of six June 30, 2019 not September 30, 2019, $579,000 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered nonlease components. In the contracts with lease and nonlease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2019 December 31, 2018. $470,000, not September 30, 2019 $686,000 December 31, 2018. The following table reflects the changes in our customer contract liabilities for the nine September 30, 2019: September 30, December 31, Nine Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 470 $ 639 $ (169 ) Other - 47 (47 ) Total $ 470 $ 686 $ (216 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2019 2018, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $198,000 $0 September 30, 2019 2018, three nine September 30, 2019, $30,000 $0 2018 no six Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 652 $ 3,455 $ 3,106 $ 10,613 Asia Pacific 373 717 1,684 2,238 Europe and Middle East 27 612 316 1,143 Latin America - 37 10 51 Total $ 1,052 $ 4,821 $ 5,116 $ 14,045 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2019 2018. Product Warranty The Company’s products are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2019 2018, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2019 2018 Stock options to purchase common stock 50,471 42,917 Warrants to purchase common stock 5,549 6,408 Restricted common stock awards 3,432 600 Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no September 30, 2019 December 31, 2018. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of September 30, 2019, December 31, 2018 There were no

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not September 30, 2019, 4,800 zero $27,000 three nine September 30, 2019 no September 30, 2019 December 31, 2018. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not September 30, 2019, 7% three three nine September 30, 2019, $168,000 $431,000, three nine September 30, 2018, $132,000 $539,000, In February 2019, no

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of September 30, 2019 December 31, 2018 ( September 30, December 31, 2019 2018 Accrued bonuses $ 728 $ 837 Accrued interest 704 683 Deferred revenue - subscription rental program 579 - Accrued payroll and other related expenses 500 877 Accrued professional fees 494 978 Customer contracts liabilities 470 686 Accrued sales commission 423 1,743 Current operating lease liabilities 257 - Accrued clinical trial costs 166 84 Travel and entertainment 54 280 Accrued sales & use tax 9 259 Other accruals 73 339 Total accrued liabilities $ 4,457 $ 6,766

Note 6 - Note Payable

Note 6 - Note Payable	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may The 2017 six four 2017 12.5%, 4.0% may, three nine September 30, 2019, $331,000 $973,000, three nine September 30, 2018, $318,000 $934,000, 5.0% September 30, 2019, $756,000 The Company may 2017 first five no As security for its obligations under the 2017 The terms of the 2017 $2.0 2022, not 2.0 2017 September 30, 2019, As of September 30, 2019 December 31, 2018, $31,694,000 $30,528,000, 2017 In connection with the 2017 two 10 2,220 $950.00 9 As of September 30, 2019, Year Ending December 31, 2019 (remaining three months) $ 710 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 45,810 Less: Amount representing interest (13,087 ) Present value of obligations 32,723 Less: Unamortized debt discount (1,029 ) Note payable, noncurrent portion $ 31,694

Note 7 - Leases

Note 7 - Leases	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. In January 2012, March 2012 April 2018. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the three nine September 30, 2018 $65,000 $293,000. In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at September 30, 2019 January 1, 2019 ( September 30, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 456 $ 629 Liabilities: Current operating lease liabilities $ 257 $ 230 Noncurrent operating lease liabilities 203 399 $ 460 $ 629 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the three nine September 30, 2019 $75,000 $225,000, As of September 30, 2019, Year Ending December 31, 2019 (remaining three months) $ 75 2020 303 2021 136 Total lease payments 514 Less: Amount representing interest (54 ) Present value of lease liabilities $ 460 The weighted average remaining lease term was approximately 20 September 30, 2019. three nine September 30, 2019 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of September 30, 2019, Year Ending December 31, 2019 (remaining three months) $ 255 2020 324 Thereafter - Total $ 579 As of September 30, 2019, $456,000 three nine September 30, 2019 $46,000 $46,000,

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 9 - Common Stock

Note 9 - Common Stock	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Common Stock Through the August 2019 may $6,760,000 $6,760,000 August 2019 September 2019. three September 30, 2019, 1,004,171 August 2019 $6,322,000. In August 2019, November 2017 $25,000,000 three nine September 30, 2019, zero November 2017 three nine September 30, 2018, 37 2,771 November 2017 $11,000 $1,194,000, November 2017 August 2019, 3,364 $1,318,000. In March 2019, 274 $25,000. In December 2018, December 2018 147,285 $22,093,000. $20,385,000. In June 2018, 1,000 $256,000. In February 2018, February 2018 115,000 $34,500,000. $32,214,000. Warrants for Common Stock As of September 30, 2019, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants October 2014 Common Shares October 13, 2019 $ 424.00 288 November 2014 Common Shares November 12, 2019 $ 424.00 125 February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 5,549 In connection with the 2017 2,220, $950.00 ten $940,000 0%, 55.1%, 2.25% ten $790,000, three nine September 30, 2019, $92,000 $270,000, three nine September 30, 2018, $82,000 $242,000, No three nine September 30, 2019 2018. No three nine September 30, 2019 2018. A total of 859 three nine September 30, 2019. No three nine September 30, 2018.

Note 10 - Summary of Stock Opti

Note 10 - Summary of Stock Options	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of September 30, 2019, 2006 104 no $992.00 3.3 As of September 30, 2019, 2013 50,367 11,770 $297.56 8.3 In January 2019, 2019 2013 20,431 49,140 69,571 January 1, 2019. In September 2019, 2013 18% 1 $5.0 2 December 31, 2019. Activity under the 2006 2013 Nine Months Ended September 30, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 40,144 $ 456.00 7.4 $ - Options granted 23,344 $ 117.91 Options exercised - Options canceled (13,017 ) $ 457.34 Options outstanding, end of period 50,471 $ 298.99 8.3 $ - Vested and exercisable and expected to vest, end of period 48,506 $ 302.18 8.3 $ - Vested and exercisable, end of period 21,169 $ 397.45 7.4 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of September 30, 2019. The options outstanding and exercisable as of September 30, 2019 Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2019 Price Term (Years) September 30, 2019 Price $38.00 - $58.00 1,650 $ 55.42 9.7 - $ - $100.00 - $197.00 25,496 $ 138.25 9.1 6,839 $ 148.08 $202.00 - $283.00 775 $ 252.06 8.3 305 $ 258.36 $311.00 - $382.00 4,377 $ 357.96 8.1 2,318 $ 360.44 $430.00 - $497.00 8,908 $ 452.58 7.7 4,576 $ 454.70 $501.00 - $567.00 4,594 $ 536.63 6.9 3,126 $ 536.17 $600.00 - $661.00 2,397 $ 601.91 5.9 2,236 $ 601.42 $700.00 - $792.00 2,170 $ 769.23 6.3 1,665 $ 769.86 $992.00 - $992.00 104 $ 992.00 3.3 104 $ 992.00 Total: 50,471 $ 298.99 8.3 21,169 $ 397.45 Restricted Stock Awards (‘RSA”) In July 2019, 378 2013 $38.08 378 In June 2019, 250 June 2018. In April 2019, 525 2013 $91.00 525 In January 2019, 3,625 2013 2018 2018 50% 50% three nine September 30, 2019, 421 443 September 30, 2019, zero As of September 30, 2019, 3,432 2017 The eighth 2017 “2017 July 1, 2019 September 30, 2019, 200 September 30, 2019 $3.75. The seventh 2017 April 1, 2019 June 30, 2019, 602 June 28, 2019 $32.30. The sixth 2017 January 1, 2019 March 31, 2019, 429 March 29, 2019 $79.88. As of September 30, 2019, 2017 1,392 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 98 % 67 % 84 % 67 % Risk-free interest rate 2.21 % 1.93 % 2.40 % 1.71 % Dividend yield 0 % 0 % 0 % 0 % The weighted average grant date fair value of the purchase rights issued under the 2017 three nine September 30, 2019 $13.16 $2.12, three nine September 30, 2018 $75.00 $100.00, Stock-Based Compensation During the three September 30, 2019, not three September 30, 2018, 2,375 $301.17 nine September 30, 2019 2018, 23,069 20,544 $117.86 $364.98 no three nine September 30, 2019 2018. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 5 5 5 Average volatility N/A 70 % 73 % 73 % Risk-free interest rate N/A 2.86 % 2.49 % 2.67 % Dividend yield N/A 0 % 0 % 0 % During the three September 30, 2019, not nine September 30, 2019, 275 $121.82. three nine September 30, 2018, 100 2,123 $283.00 $241.69 no three nine September 30, 2019 2018. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 10 5 10 Average volatility N/A 66 % 73 % 66 % Risk-free interest rate N/A 3.04 % 2.49 % 3.04 % Dividend yield N/A 0 % 0 % 0 % Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Cost of revenue $ 25 $ 19 $ 91 $ 47 Research and development 41 79 134 266 Selling, general and administrative 451 667 1,409 1,981 Total $ 517 $ 765 $ 1,634 $ 2,294 As of September 30, 2019, $3,371,000. 2.2

Note 11 - Income Taxes

Note 11 - Income Taxes	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	11. Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three nine September 30, 2019. 2019 0%.

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions In June 2006, October 4, 2007. 300 September 30, 2019, 855 375 $720,000 $3,015,000 three September 30, 2019 2018, $3,853,000 $8,613,000 nine September 30, 2019 2018, September 30, 2019 December 31, 2018 456,000 $960,000,

Note 13 - Restructuring Costs

Note 13 - Restructuring Costs	9 Months Ended
	Sep. 30, 2019
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	13. Restructuring Costs In January 2019, 40 $742,000 September 30, 2019, first 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reserve Stock Split, Policy [Policy Text Block]	Reverse Stock Split On September 18, 2019, 1 100 September 18, 2019. not No The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75 The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Changes in Accounting Policies, Policy [Policy Text Block]	Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard - Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2019, two 31 three September 30, 2018, three 42% nine September 30, 2019, one 17 nine September 30, 2018, one 21% There were no 10% three nine September 30, 2019 2018. As of September 30, 2019, four 67% December 31, 2018, three 54%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $543,000 September 30, 2019 $284,000 December 31, 2018.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System have a rental period of six June 30, 2019 not In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered nonlease components. In the contracts with lease and nonlease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2019 December 31, 2018. $470,000, not September 30, 2019 $686,000 December 31, 2018. The following table reflects the changes in our customer contract liabilities for the nine September 30, 2019: September 30, December 31, Nine Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 470 $ 639 $ (169 ) Other - 47 (47 ) Total $ 470 $ 686 $ (216 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2019 2018, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $198,000 $0 September 30, 2019 2018, three nine September 30, 2019, $30,000 $0 2018 no six Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 652 $ 3,455 $ 3,106 $ 10,613 Asia Pacific 373 717 1,684 2,238 Europe and Middle East 27 612 316 1,143 Latin America - 37 10 51 Total $ 1,052 $ 4,821 $ 5,116 $ 14,045 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2019 2018.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company’s products are generally subject to warranties between one three not
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2019 2018,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2019 2018 Stock options to purchase common stock 50,471 42,917 Warrants to purchase common stock 5,549 6,408 Restricted common stock awards 3,432 600
New Accounting Pronouncements, Policy [Policy Text Block]	Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block]	Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463
Contract with Customer, Asset and Liability [Table Text Block]	September 30, December 31, Nine Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 470 $ 639 $ (169 ) Other - 47 (47 ) Total $ 470 $ 686 $ (216 )
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 652 $ 3,455 $ 3,106 $ 10,613 Asia Pacific 373 717 1,684 2,238 Europe and Middle East 27 612 316 1,143 Latin America - 37 10 51 Total $ 1,052 $ 4,821 $ 5,116 $ 14,045
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Nine Months Ended September 30, 2019 2018 Stock options to purchase common stock 50,471 42,917 Warrants to purchase common stock 5,549 6,408 Restricted common stock awards 3,432 600

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2019 2018 Accrued bonuses $ 728 $ 837 Accrued interest 704 683 Deferred revenue - subscription rental program 579 - Accrued payroll and other related expenses 500 877 Accrued professional fees 494 978 Customer contracts liabilities 470 686 Accrued sales commission 423 1,743 Current operating lease liabilities 257 - Accrued clinical trial costs 166 84 Travel and entertainment 54 280 Accrued sales & use tax 9 259 Other accruals 73 339 Total accrued liabilities $ 4,457 $ 6,766

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2019 (remaining three months) $ 710 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 45,810 Less: Amount representing interest (13,087 ) Present value of obligations 32,723 Less: Unamortized debt discount (1,029 ) Note payable, noncurrent portion $ 31,694

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	September 30, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 456 $ 629 Liabilities: Current operating lease liabilities $ 257 $ 230 Noncurrent operating lease liabilities 203 399 $ 460 $ 629
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2019 (remaining three months) $ 75 2020 303 2021 136 Total lease payments 514 Less: Amount representing interest (54 ) Present value of lease liabilities $ 460
Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block]	Year Ending December 31, 2019 (remaining three months) $ 255 2020 324 Thereafter - Total $ 579

Note 9 - Common Stock (Tables)

Note 9 - Common Stock (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants October 2014 Common Shares October 13, 2019 $ 424.00 288 November 2014 Common Shares November 12, 2019 $ 424.00 125 February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 5,549

Note 10 - Summary of Stock Op_2

Note 10 - Summary of Stock Options (Tables)	9 Months Ended
	Sep. 30, 2019
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 40,144 $ 456.00 7.4 $ - Options granted 23,344 $ 117.91 Options exercised - Options canceled (13,017 ) $ 457.34 Options outstanding, end of period 50,471 $ 298.99 8.3 $ - Vested and exercisable and expected to vest, end of period 48,506 $ 302.18 8.3 $ - Vested and exercisable, end of period 21,169 $ 397.45 7.4 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2019 Price Term (Years) September 30, 2019 Price $38.00 - $58.00 1,650 $ 55.42 9.7 - $ - $100.00 - $197.00 25,496 $ 138.25 9.1 6,839 $ 148.08 $202.00 - $283.00 775 $ 252.06 8.3 305 $ 258.36 $311.00 - $382.00 4,377 $ 357.96 8.1 2,318 $ 360.44 $430.00 - $497.00 8,908 $ 452.58 7.7 4,576 $ 454.70 $501.00 - $567.00 4,594 $ 536.63 6.9 3,126 $ 536.17 $600.00 - $661.00 2,397 $ 601.91 5.9 2,236 $ 601.42 $700.00 - $792.00 2,170 $ 769.23 6.3 1,665 $ 769.86 $992.00 - $992.00 104 $ 992.00 3.3 104 $ 992.00 Total: 50,471 $ 298.99 8.3 21,169 $ 397.45
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 5 5 5 Average volatility N/A 70 % 73 % 73 % Risk-free interest rate N/A 2.86 % 2.49 % 2.67 % Dividend yield N/A 0 % 0 % 0 % Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 10 5 10 Average volatility N/A 66 % 73 % 66 % Risk-free interest rate N/A 3.04 % 2.49 % 3.04 % Dividend yield N/A 0 % 0 % 0 %
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Cost of revenue $ 25 $ 19 $ 91 $ 47 Research and development 41 79 134 266 Selling, general and administrative 451 667 1,409 1,981 Total $ 517 $ 765 $ 1,634 $ 2,294
2017 Employee Stock Purchase Plan [Member]
Notes Tables
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 98 % 67 % 84 % 67 % Risk-free interest rate 2.21 % 1.93 % 2.40 % 1.71 % Dividend yield 0 % 0 % 0 % 0 %

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Aug. 16, 2019	Feb. 12, 2018	Nov. 08, 2017	Aug. 31, 2019	Dec. 31, 2018		Feb. 28, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017
Proceeds from Issuance of Common Stock										$ 6,322,000	$ 33,407,000
Retained Earnings (Accumulated Deficit), Ending Balance					$ (155,385,000)	[1]		$ (183,094,000)		(183,094,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance					$ 29,523,000	[1]		9,086,000	$ 20,097,000	9,086,000	20,097,000	$ 20,730,000
Working Capital								12,836,000		12,836,000
Net Cash Provided by (Used in) Operating Activities, Total								$ (6,608,000)		$ (25,862,000)	$ (33,245,000)
August 2019 ATM Facility [Member]
Aggregate Offering Price	$ 6,760,000			$ 6,760,000
Stock Issued During Period, Shares, New Issues								1,004,171
Proceeds From Issuance of Common Stock, Net								$ 6,322,000
November 2017 ATM Facility [Member]
Aggregate Offering Price			$ 25,000,000	$ 25,000,000
Stock Issued During Period, Shares, New Issues				3,364				0	37	0	2,771
Proceeds From Issuance of Common Stock, Net				$ 1,318,000				$ 11,000	$ 11,000	$ 1,194,000	$ 1,194,000
December 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues					147,285
Proceeds From Issuance of Common Stock, Net					$ 20,385,000
Proceeds from Issuance of Common Stock					$ 22,093,000
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues							115,000
Proceeds From Issuance of Common Stock, Net		$ 32,214,000					$ 32,214,000
Proceeds from Issuance of Common Stock		$ 34,500,000					$ 34,500,000
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Sep. 18, 2019	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Jun. 30, 2019	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)$ / sharesshares		Jan. 01, 2019USD ($)
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.0001			$ 0.0001		$ 0.0001	[1]
Common Stock, Shares Authorized | shares		75,000,000			75,000,000		75,000,000	[1]
Operating Lease, Right-of-Use Asset		$ 456,000			$ 456,000				$ 629,000
Operating Lease, Liability, Total		$ 460,000			$ 460,000				$ 629,000
Number of Financial Institutions		1			1
Accounts Receivable, Allowance for Credit Loss, Ending Balance		$ 543,000			$ 543,000		$ 284,000
Deferred Income		579,000			579,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		0			0		0
Contract with Customer, Liability, Total		470,000			470,000		$ 686,000
Capitalized Contract Cost, Net, Total		198,000	$ 0		198,000	$ 0
Capitalized Contract Cost, Amortization		30,000	0		30,000	0
Equity Method Investment, Other than Temporary Impairment		$ 0	$ 0		$ 0	$ 0
Minimum [Member]
Warranty Period				1 year
Maximum [Member]
Warranty Period				3 years
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers		2	3		1	1
Concentration Risk, Percentage			42.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage					17.00%	21.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers					4		3
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Customers [Member]
Concentration Risk, Percentage					67.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage							54.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	100
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands		Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018	[1]
Other assets		$ 587	$ 800	$ 171
Total assets		24,149	47,463	46,834
Total accrued liabilities		4,457	6,996	6,766
Total current liabilities		6,248	10,990	10,760
Other noncurrent liabilities		997	1,033	634
Total liabilities		38,939	42,551	41,922
Total liabilities and stockholders' equity		$ 24,149	47,463	$ 46,834
Accounting Standards Update 2016-02 [Member]
Other assets	[2]		629
Total assets	[2]		629
Total accrued liabilities	[3]		230
Total current liabilities	[3]		230
Other noncurrent liabilities	[3]		399
Total liabilities	[3]		629
Total liabilities and stockholders' equity	[3]		$ 629
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.
[2]	Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent.
[3]	Represents recognition of operating lease liabilities.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Customer contract liabilities	$ 470,000	$ 686,000
Change in customer contract liabilities	(216,000)
Marketing Programs [Member]
Customer contract liabilities	470,000	639,000
Change in customer contract liabilities	(169,000)
Product and Service, Other [Member]
Customer contract liabilities		$ 47,000
Change in customer contract liabilities	$ (47,000)

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue	$ 1,052	$ 4,821	$ 5,116	$ 14,045
North America [Member]
Revenue	652	3,455	3,106	10,613
Asia Pacific [Member]
Revenue	373	717	1,684	2,238
Europe And Middle East [Member]
Revenue	27	612	316	1,143
Latin America [Member]
Revenue		$ 37	$ 10	$ 51

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	50,471	42,917
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	5,549	6,408
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	3,432	600

Note 4 - Investment in Limite_2

Note 4 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Income (Loss) from Equity Method Investments, Total		$ (168,000)	$ (132,000)	$ (431,000)	$ (539,000)
Membership Unit Subscription Agreement [Member] | InControl Medical [Member]
Accounts Payable, Related Parties, Current		$ 0		$ 0		$ 0
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		7.00%		7.00%
Income (Loss) from Equity Method Investments, Total		$ (168,000)	$ (132,000)	$ (431,000)	$ (539,000)
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased				4,800
Payments for Purchase of Products		$ 0		$ 27,000
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Accrued bonuses	$ 728		$ 837
Accrued interest	704		683
Deferred revenue - subscription rental program	579
Accrued payroll and other related expenses	500		877
Accrued professional fees	494		978
Customer contracts liabilities	470		686
Accrued sales commission	423		1,743
Current operating lease liabilities	257	$ 230
Accrued clinical trial costs	166		84
Travel and entertainment	54		280
Accrued sales & use tax	9		259
Other accruals	73		339
Total accrued liabilities	$ 4,457	$ 6,996	$ 6,766	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	Dec. 29, 2017	May 22, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Interest Payable			$ 13,087,000		$ 13,087,000
Notes Payable, Noncurrent, Total			$ 31,694,000		$ 31,694,000		$ 30,528,000	[1]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,549		5,549
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term		10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		2,220	2,220		2,220
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 950	$ 950		$ 950
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount		$ 20,000,000
Debt Agreement, Covenant, Additional Funding		10,000,000
Debt Agreement, Maximum Borrowing Capacity		$ 30,000,000
Proceeds from Lines of Credit, Total	$ 10,000,000
Debt Instrument, Term		6 years
Debt instrument, Interest Only Payment, Period		4 years
Debt Instrument, Interest Rate, Stated Percentage		12.50%
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period		4.00%
Paid-in-Kind Interest			$ 331,000	$ 318,000	$ 973,000	$ 934,000
Debt Instrument, Prepayment Fee, Percentage		5.00%
Debt Instrument, Prepayment Fee, Period of Term		5 years
Debt Instrument, Covenant, Cash and Cash Equivalents		$ 2,000,000
Notes Payable, Noncurrent, Total			31,694,000		31,694,000		$ 30,528,000
The 2017 Loan Agreement [Member] | CRG LP [Member] | Other Noncurrent Liabilities [Member]
Interest Payable			$ 756,000		$ 756,000
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018	[1]
2019 (remaining three months)	$ 710
2020	2,901
2021	16,673
2022	19,306
2023	6,220
Total payments	45,810
Less: Amount representing interest	(13,087)
Present value of obligations	32,723
Less: Unamortized debt discount	(1,029)
Note payable, noncurrent portion	$ 31,694	$ 30,528
[1]	The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Feb. 01, 2017USD ($)ft²
Operating Leases, Rent Expense, Total			$ 65,000		$ 293,000
Operating Lease, Cost		$ 75,000		$ 225,000
Operating Lease, Weighted Average Discount Rate, Percent		12.50%		12.50%
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property | ft²						12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year						20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year						21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year						21.75
Security Deposit						$ 22,000
Operating Leases, Allowance for Certain Improvements						$ 88,000
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract	3 years		3 years		3 years
Operating Leases, Monthly Payment	$ 3,000
Leases of Viveve Systems [Member]
Operating Lease, Property Plant and Equipment, Amount		$ 456,000		$ 456,000
Lessor, Operating Lease, Depreciation on Leased Assets		$ 46,000		$ 46,000

Note 7 - Leases - Lease Assets

Note 7 - Leases - Lease Assets and Liabilities (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Right-of-Use Asset	$ 456,000	$ 629,000
Current operating lease liabilities	257,000	230,000
Noncurrent operating lease liabilities	203,000	399,000
	$ 460,000	$ 629,000

Note 7 - Leases - Maturity of O

Note 7 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($)	Sep. 30, 2019	Jan. 01, 2019
2019 (remaining three months)	$ 75,000
2020	303,000
2021	136,000
Total lease payments	514,000
Less: Amount representing interest	(54,000)
Present value of lease liabilities	$ 460,000	$ 629,000

Note 7 - Leases - Minimum Futur

Note 7 - Leases - Minimum Future Rentals (Details) $ in Thousands	Sep. 30, 2019USD ($)
2019 (remaining three months)	$ 255
2020	324
Thereafter
Total	$ 579

Note 9 - Common Stock (Details

Note 9 - Common Stock (Details Textual)	Aug. 16, 2019USD ($)	Feb. 12, 2018USD ($)	Nov. 08, 2017USD ($)	Aug. 31, 2019USD ($)shares	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)shares	Jun. 30, 2018USD ($)shares	Feb. 28, 2018USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	May 22, 2017USD ($)yr$ / sharesshares
Stock Issued During Period, Value, Restricted Stock Award, Gross							$ 256,000		$ 14,000	$ 47,000	$ 67,000	$ 108,000
Proceeds from Issuance of Common Stock													$ 6,322,000	$ 33,407,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares							1,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									5,549				5,549
Class of Warrants or Rights, Exercises in Period | shares									0	0			0	0
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period | shares										0			0	0
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period | shares									859	0			859	0
The 2017 Loan Agreement [Member]
Debt Issuance Costs, Net, Total									$ 790,000				$ 790,000
Amortization of Debt Discount (Premium)									$ 92,000	$ 82,000			$ 270,000	$ 242,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares									2,220				2,220		2,220
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 950				$ 950		$ 950
Warrants and Rights Outstanding, Term															10 years
Warrants and Rights Outstanding															$ 940,000
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input															0
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input															0.551
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input															0.0225
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr															10
Restricted Stock [Member]
Proceeds From Issuance of Common Stock, Net					$ 274
Stock Issued During Period, Value, Restricted Stock Award, Gross					$ 25,000
August 2019 ATM Facility [Member]
Aggregate Offering Price	$ 6,760,000			$ 6,760,000
Stock Issued During Period, Shares, New Issues | shares									1,004,171
Proceeds From Issuance of Common Stock, Net									$ 6,322,000
November 2017 ATM Facility [Member]
Aggregate Offering Price			$ 25,000,000	$ 25,000,000
Stock Issued During Period, Shares, New Issues | shares				3,364					0	37			0	2,771
Proceeds From Issuance of Common Stock, Net				$ 1,318,000					$ 11,000	$ 11,000			$ 1,194,000	$ 1,194,000
December 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares						147,285
Proceeds From Issuance of Common Stock, Net						$ 20,385,000
Proceeds from Issuance of Common Stock						$ 22,093,000
February 2018 Offering [Member]
Stock Issued During Period, Shares, New Issues | shares								115,000
Proceeds From Issuance of Common Stock, Net		$ 32,214,000						$ 32,214,000
Stock Issued During Period, Value, Restricted Stock Award, Gross		115,000
Proceeds from Issuance of Common Stock		$ 34,500,000						$ 34,500,000

Note 9 - Common Stock - Summary

Note 9 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2019	May 22, 2017
Shares Outstanding Under Warrants (in shares)	5,549
Vendors and Contractor Warrants, October 2014 Issuance [Member]
Expiration Date	Oct. 13, 2019
Exercise Price (in dollars per share)	$ 424
Shares Outstanding Under Warrants (in shares)	288
Vendors and Contractor Warrants, November 2014 Issuance [Member]
Expiration Date	Nov. 12, 2019
Exercise Price (in dollars per share)	$ 424
Shares Outstanding Under Warrants (in shares)	125
Employee Performance Bonus Warrants, February 2015 Issuance [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share)	$ 400
Shares Outstanding Under Warrants (in shares)	754
Contractor Warrants, March 2015 Issuance [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share)	$ 272
Shares Outstanding Under Warrants (in shares)	14
Contractor Warrants, May 2015 Issuance [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share)	$ 424
Shares Outstanding Under Warrants (in shares)	362
May 2015 Issuance Second Contractor [Member]
Expiration Date	May 17, 2020
Exercise Price (in dollars per share)	$ 424
Shares Outstanding Under Warrants (in shares)	215
Performance Bonus Warrants, December 2015 Issuance [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share)	$ 560
Shares Outstanding Under Warrants (in shares)	267
Distributor Warrants, April 2016 Issuance [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share)	$ 608
Shares Outstanding Under Warrants (in shares)	250
Contractor Warrants, May 2016 Issuance [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share)	$ 774
Shares Outstanding Under Warrants (in shares)	50
June 2016 Issuance Related to 2016 Loan Agreement [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share)	$ 498
Shares Outstanding Under Warrants (in shares)	1,004
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share)	$ 950	$ 950
Shares Outstanding Under Warrants (in shares)	2,220	2,220

Note 10 - Summary of Stock Op_3

Note 10 - Summary of Stock Options (Details Textual) - USD ($)	1 Months Ended						3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jul. 31, 2019	Jun. 30, 2019	Apr. 30, 2019	Jan. 31, 2019	Jun. 30, 2018	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jan. 01, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	50,471						50,471				50,471		40,144
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 298.99						$ 298.99				$ 298.99		$ 456
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term											8 years 109 days		7 years 146 days
Stock Issued During Period, Shares, Restricted Stock Award, Gross						1,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance	3,432						3,432				3,432
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											23,344
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate										0.00%	0.00%	0.00%
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate											0.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 3,371,000						$ 3,371,000				$ 3,371,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition											2 years 73 days
Director [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross		378		525
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period				525
Director [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 38.08		$ 91
Consultant [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross			250
Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate										0.00%	0.00%	0.00%
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	104						104				104
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	0						0				0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 992						$ 992				$ 992
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term											3 years 109 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	50,367						50,367				50,367
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 297.56						$ 297.56				$ 297.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term											8 years 109 days
Common Stock, Capital Shares Reserved for Future Issuance	11,770						11,770				11,770
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized					20,431
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized													49,140	69,571
Common Stock Shares Reserved For Future Issuance Percentage	18.00%						18.00%				18.00%
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period					3,625
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period							421				443
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period											0
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total											0
The 2013 Plan [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										2,375	23,069	20,544
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 301.17	$ 117.86	$ 364.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							0			0	0	0
The 2013 Plan [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							0			100	275	2,123
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value										$ 283	$ 121.82	$ 241.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							0			0	0	0
The 2013 Plan [Member] | Underwritten Public Offering [Member]
Minimum Gross Proceeds From Equity Offering Amount Used In Calculation Of Reserved Shares Percentage	$ 5,000,000
2017 Employee Stock Purchase Plan [Member]
Stock Issued During Period, Shares, Employee Stock Purchase Plans							200	602	429
Shares Issued, Price Per Share	$ 3.75		$ 32.30				$ 3.75	$ 32.30	$ 79.88		$ 3.75
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares	1,392						1,392				1,392
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased							$ 13.16			$ 75	$ 2.12	$ 100
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate							0.00%			0.00%	0.00%	0.00%

Note 10 - Summary of Stock Op_4

Note 10 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2018$ / sharesshares
Options outstanding (in shares) | shares	40,144
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 456
Options outstanding, weighted average remaining contractual term (Year)	8 years 109 days	7 years 146 days
Options granted (in shares) | shares	23,344
Options granted, weighted average exercise price (in dollars per share) | $ / shares	$ 117.91
Options exercised (in shares) | shares
Options exercised, weighted average exercise price (in dollars per share) | $ / shares
Options canceled (in shares) | shares	(13,017)
Options canceled, weighted average exercise price (in dollars per share) | $ / shares	$ 457.34
Options outstanding (in shares) | shares	50,471	40,144
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 298.99	$ 456
Options outstanding, aggregate intrinsic value | $
Vested and exercisable and expected to vest, end of period (in shares) | shares	48,506
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 302.18
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	8 years 109 days
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value | $
Vested and exercisable, end of period (in shares) | shares	21,169
Vested and exercisable, end of period, weighted average exercise price (in dollars per share) | $ / shares	$ 397.45
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	7 years 146 days
Vested and exercisable, end of period, aggregate intrinsic value | $

Note 10 - Summary of Stock Op_5

Note 10 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Options outstanding, number (in shares) | shares	50,471
Options outstanding, weighted average exercise price (in dollars per share)	$ 298.99
Options outstanding, weighted average remaining contractual term (Year)	8 years 109 days
Options exercisable, number exercisable (in shares) | shares	21,169
Options exercisable, weighted average exercise price (in dollars per share)	$ 397.45
Range One [Member]
Exercise price range, lower limit (in dollars per share)	38
Exercise price range, upper limit (in dollars per share)	$ 58
Options outstanding, number (in shares) | shares	1,650
Options outstanding, weighted average exercise price (in dollars per share)	$ 55.42
Options outstanding, weighted average remaining contractual term (Year)	9 years 255 days
Options exercisable, number exercisable (in shares) | shares
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	$ 100
Exercise price range, upper limit (in dollars per share)	$ 197
Options outstanding, number (in shares) | shares	25,496
Options outstanding, weighted average exercise price (in dollars per share)	$ 138.25
Options outstanding, weighted average remaining contractual term (Year)	9 years 36 days
Options exercisable, number exercisable (in shares) | shares	6,839
Options exercisable, weighted average exercise price (in dollars per share)	$ 148.08
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	202
Exercise price range, upper limit (in dollars per share)	$ 283
Options outstanding, number (in shares) | shares	775
Options outstanding, weighted average exercise price (in dollars per share)	$ 252.06
Options outstanding, weighted average remaining contractual term (Year)	8 years 109 days
Options exercisable, number exercisable (in shares) | shares	305
Options exercisable, weighted average exercise price (in dollars per share)	$ 258.36
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	311
Exercise price range, upper limit (in dollars per share)	$ 382
Options outstanding, number (in shares) | shares	4,377
Options outstanding, weighted average exercise price (in dollars per share)	$ 357.96
Options outstanding, weighted average remaining contractual term (Year)	8 years 36 days
Options exercisable, number exercisable (in shares) | shares	2,318
Options exercisable, weighted average exercise price (in dollars per share)	$ 360.44
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	430
Exercise price range, upper limit (in dollars per share)	$ 497
Options outstanding, number (in shares) | shares	8,908
Options outstanding, weighted average exercise price (in dollars per share)	$ 452.58
Options outstanding, weighted average remaining contractual term (Year)	7 years 255 days
Options exercisable, number exercisable (in shares) | shares	4,576
Options exercisable, weighted average exercise price (in dollars per share)	$ 454.70
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	501
Exercise price range, upper limit (in dollars per share)	$ 567
Options outstanding, number (in shares) | shares	4,594
Options outstanding, weighted average exercise price (in dollars per share)	$ 536.63
Options outstanding, weighted average remaining contractual term (Year)	6 years 328 days
Options exercisable, number exercisable (in shares) | shares	3,126
Options exercisable, weighted average exercise price (in dollars per share)	$ 536.17
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	600
Exercise price range, upper limit (in dollars per share)	$ 661
Options outstanding, number (in shares) | shares	2,397
Options outstanding, weighted average exercise price (in dollars per share)	$ 601.91
Options outstanding, weighted average remaining contractual term (Year)	5 years 328 days
Options exercisable, number exercisable (in shares) | shares	2,236
Options exercisable, weighted average exercise price (in dollars per share)	$ 601.42
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	700
Exercise price range, upper limit (in dollars per share)	$ 792
Options outstanding, number (in shares) | shares	2,170
Options outstanding, weighted average exercise price (in dollars per share)	$ 769.23
Options outstanding, weighted average remaining contractual term (Year)	6 years 109 days
Options exercisable, number exercisable (in shares) | shares	1,665
Options exercisable, weighted average exercise price (in dollars per share)	$ 769.86
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	992
Exercise price range, upper limit (in dollars per share)	$ 992
Options outstanding, number (in shares) | shares	104
Options outstanding, weighted average exercise price (in dollars per share)	$ 992
Options outstanding, weighted average remaining contractual term (Year)	3 years 109 days
Options exercisable, number exercisable (in shares) | shares	104
Options exercisable, weighted average exercise price (in dollars per share)	$ 992

Note 10 - Summary of Stock Op_6

Note 10 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Expected term (Year)		5 years	5 years	5 years
Average volatility		70.00%	73.00%	73.00%
Risk-free interest rate		2.86%	2.49%	2.67%
Dividend yield		0.00%	0.00%	0.00%
2017 Employee Stock Purchase Plan [Member]
Expected term (Year)	91 days	91 days	91 days	91 days
Average volatility	98.00%	67.00%	84.00%	67.00%
Risk-free interest rate	2.21%	1.93%	2.40%	1.71%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Note 10 - Summary of Stock Op_7

Note 10 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Expected term (Year)		5 years	5 years	5 years
Average volatility		70.00%	73.00%	73.00%
Risk-free interest rate		2.86%	2.49%	2.67%
Dividend yield		0.00%	0.00%	0.00%
Nonemployees [Member]
Expected term (Year)		10 years	5 years	10 years
Average volatility		66.00%	73.00%	66.00%
Risk-free interest rate		3.04%	2.49%	3.04%
Dividend yield		0.00%	0.00%	0.00%

Note 10 - Summary of Stock Op_8

Note 10 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock-based compensation expense	$ 517	$ 765	$ 1,634	$ 2,294
Cost of Sales [Member]
Stock-based compensation expense	25	19	91	47
Research and Development Expense [Member]
Stock-based compensation expense	41	79	134	266
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 451	$ 667	$ 1,409	$ 1,981

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2019
Income Tax Expense (Benefit), Total		$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%
Forecast [Member]
Effective Income Tax Rate Reconciliation, Percent, Total			0.00%

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	3 Months Ended		9 Months Ended		120 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Dec. 31, 2018
Stock Issued During Period, Shares, New Issues					375
Related Party Transaction, Amounts of Transaction	$ 720,000	$ 3,015,000	$ 3,853,000	$ 8,613,000
Accounts Payable, Related Parties, Current	$ 456,000		$ 456,000		$ 456,000	$ 960,000

Note 13 - Restructuring Costs (

Note 13 - Restructuring Costs (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	40
Restructuring Charges, Total	$ 742,000			$ 742,000